Biofrontera Inc (BFRI)

概要ニュース株価時系列 Financials ディスカッション予測株式分割

Relative Volume:

ネットキャッシュフロー:

Biofrontera Inc Stock (BFRI) Company Profile

Biofrontera Inc

Healthcare (1200)

781-245-1325

120 PRESIDENTIAL WAY,, WOBURN

BFRI's Discussions on Twitter

BFRI を他の銘柄と比較する

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
BFRI Biofrontera Inc	0.99	7.67M	34.07M	-20.13M	-24.90M	-17.12
ZTS Zoetis Inc	176.74	80.59B	9.15B	2.43B	2.31B	4.92
HLN Haleon Plc Adr	9.72	44.17B	14.26B	1.55B	0	0.3327
TAK Takeda Pharmaceutical Co Adr	13.57	42.61B	30.27B	1.93B	3.45B	0.444
TEVA Teva Pharmaceutical Industries Ltd Adr	16.57	18.77B	16.77B	-959.00M	1.37B	-2.00
VTRS Viatris Inc	13.22	15.73B	15.05B	-883.30M	1.89B	1.53

Biofrontera Inc (BFRI) 最新ニュース

Biofrontera Inc (BFRI) 財務データ

Biofrontera Inc (BFRI)

Biofrontera Inc Stock (BFRI) Company Profile

BFRI を他の銘柄と比較する

Biofrontera Inc (BFRI) 最新ニュース

Biofrontera Closes a $4.2 Million Senior Secured Convertible Note - citybiz

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - GlobeNewswire

Biofrontera Secures $4.2M for Strategic Growth Initiatives - TipRanks

Biofrontera Secures $4.2M Financing Through Convertible Note Deal with Key Shareholders | BFRI Stock News - StockTitan

Biofrontera AG announced that it has received $4.2 million in funding - Marketscreener.com

Biofrontera Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Earnings call: Biofrontera reports modest revenue growth in Q3 2024 - Investing.com

Biofrontera Inc. (NASDAQ:BFRI) Q3 2024 Earnings Call Transcript - Insider Monkey

Biofrontera Inc. (BFRI) Quarterly 10-Q Report - Quartzy

ARMISTICE CAPITAL, LLC Acquires New Stake in Biofrontera Inc - GuruFocus.com

Biofrontera Inc. Reports Q3 2024 Earnings Growth - TipRanks

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates - MSN

Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewswire

Biofrontera Reports Record Ameluz Volume, Phase 3 Study Shows 76% Clearance Rate | BFRI Stock News - StockTitan

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc. - GuruFocus.com

Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance

Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia

Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance

Biofrontera Announces Promising Phase 3 Study Results - TipRanks

Biofrontera reports breakthrough in skin cancer treatment - Investing.com

Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC - TipRanks

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewswire

Actinic Keratosis Treatment Market Expected to Reach Huge - openPR

Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Yahoo Finance

Biofrontera locks phase 3 sBCC study database for analysis By Investing.com - Investing.com Australia

Biofrontera locks phase 3 sBCC study database for analysis - Investing.com India

Biofrontera Inc. Announces Database Lock Of Phase 3 Study - GlobeNewswire

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan

BFRI’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Mass. Biotech Receives FDA Approval - Streetwise Reports

Roth/MKM sets Biofrontera target at $16, reiterates buy rating By Investing.com - Investing.com South Africa

Roth/MKM sets Biofrontera target at $16, reiterates buy rating - Investing.com India

What was Biofrontera Inc (BFRI)’s performance in the last session? - US Post News

Biofrontera says FDA approves use of up to 3 tubes of Ameluz topical gel 10% - TipRanks

Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage - TipRanks

FDA approves expanded use of Biofrontera's Ameluz for AK - Investing.com

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - The Manila Times

FDA approves expanded use of Biofrontera's Ameluz for AK By Investing.com - Investing.com UK

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s - GlobeNewswire

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - StockTitan

BFRI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Ratio Examination: Biofrontera Inc (BFRI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Biotech Stocks Facing FDA Decision In October 2024 - RTTNews

Tilray Brands (TLRY) Stock Surges Amidst Market Volatility - GuruFocus.com

ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times

Biofrontera Second Quarter 2024 Earnings: €0.023 loss per share (vs €0.12 profit in 2Q 2023) - Yahoo Finance

Five PDUFA dates on FDA’s October agenda - BioCentury

Photodynamic Therapy Market Share, Trends, Size, Major Players And Forecast To 2033 - WhaTech

Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story - Simply Wall St

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference - StockTitan

Biofrontera Inc (BFRI) 財務データ

収益

当期純利益

現金流量

EPS

BFRIに似た銘柄